Publicaciones en colaboración con investigadores/as de Hospital General de Ciudad Real (35)

2024

  1. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  2. Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives

    Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Long-term outcomes of extended DAPT in a real-life cohort of consecutive STEMI patients

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 548-554

  3. ROD2 domain filamin C missense mutations exhibit a distinctive cardiac phenotype with restrictive/hypertrophic cardiomyopathy and saw-tooth myocardium

    Revista Espanola de Cardiologia, Vol. 76, Núm. 5, pp. 301-311

  4. Underwater versus conventional EMR of large nonpedunculated colorectal lesions: a multicenter randomized controlled trial

    Gastrointestinal Endoscopy, Vol. 97, Núm. 5, pp. 941-951.e2

2022

  1. Guidelines on the management of mineral and bone metabolism disorders during pregnancy and lactation

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 7, pp. 530-539

  2. Location, morphology and invasiveness of lateral spreading tumors in the colorectum differ between two large cohorts from an eastern and western country

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 6, pp. 440-449

2020

  1. Clinical validation of risk scoring systems to predict risk of delayed bleeding after EMR of large colorectal lesions

    Gastrointestinal Endoscopy, Vol. 91, Núm. 4, pp. 868-878.e3

  2. Phosphate disorders and clinical management of hypophosphatemia and hyperphosphatemia

    Endocrinologia, Diabetes y Nutricion, Vol. 67, Núm. 3, pp. 205-215

2018

  1. Circulating levels of sclerostin are associated with cardiovascular mortality

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Recommendations on the effect of antidiabetic drugs in bone

    Endocrinologia, Diabetes y Nutricion, Vol. 64, pp. 1-6

  2. Recommended vitamin D levels in the general population

    Endocrinologia, Diabetes y Nutricion, Vol. 64, pp. 7-14

2016

  1. Metabolomic profile related to cardiovascular disease in patients with type 2 diabetes mellitus: A pilot study

    Talanta, Vol. 148, pp. 135-143

  2. Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?

    Endocrine, Vol. 52, Núm. 1, pp. 54-62

  3. Serum dickkopf1 (DKK1), bone metabolism and atherosclerotic disease in patients with type 2 diabetes

    Revista de Osteoporosis y Metabolismo Mineral, Vol. 8, Núm. 1, pp. 24-29

2015

  1. Relationship between proinflammatory and antioxidant proteins with the severity of cardiovascular disease in type 2 diabetes mellitus

    International Journal of Molecular Sciences, Vol. 16, Núm. 5, pp. 9469-9483

2014

  1. Bone turnover markers in patients with prostate carcinoma: Influence of sex steroids levels

    Journal of Bone and Mineral Metabolism, Vol. 32, Núm. 1, pp. 65-70

  2. Erratum to Bone turnover markers in patients with prostate carcinoma: influence of sex steroids levels [J Bone Miner Metab, DOI 10.1007/s00774-013-0466-5]

    Journal of Bone and Mineral Metabolism

  3. FGF23 in type 2 diabetic patients: Relationship with bone metabolism and vascular disease

    Diabetes Care